Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Trimmed by Wellington Management Group LLP

Wellington Management Group LLP decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 43.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,427,952 shares of the medical research company's stock after selling 1,100,685 shares during the period. Wellington Management Group LLP owned approximately 0.38% of Thermo Fisher Scientific worth $742,863,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Howard Capital Management Group LLC increased its position in Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after purchasing an additional 286 shares during the period. Principal Financial Group Inc. grew its holdings in Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after acquiring an additional 225,568 shares during the period. Fred Alger Management LLC purchased a new position in Thermo Fisher Scientific in the third quarter worth $1,274,000. Tradition Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 3.1% during the 3rd quarter. Tradition Wealth Management LLC now owns 1,128 shares of the medical research company's stock worth $697,000 after purchasing an additional 34 shares in the last quarter. Finally, Cobblestone Capital Advisors LLC NY grew its position in Thermo Fisher Scientific by 14.6% during the third quarter. Cobblestone Capital Advisors LLC NY now owns 783 shares of the medical research company's stock worth $484,000 after buying an additional 100 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. Bank of America lowered their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a research report on Friday, January 31st. Raymond James reissued an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Finally, UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $653.23.

Thermo Fisher Scientific Trading Down 3.9 %

NYSE:TMO traded down $19.18 during trading hours on Thursday, reaching $469.88. 2,812,372 shares of the company were exchanged, compared to its average volume of 1,631,020. Thermo Fisher Scientific Inc. has a 52-week low of $468.39 and a 52-week high of $627.88. The stock has a 50 day simple moving average of $536.85 and a 200 day simple moving average of $549.69. The firm has a market cap of $177.27 billion, a price-to-earnings ratio of 28.43, a PEG ratio of 2.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.37%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 in the last 90 days. 0.34% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.